NK cell genotype and phenotype at diagnosis of acute lymphoblastic leukemia correlate with postinduction residual disease

Clinical Cancer Research

Volumn 20, Issue 23, 2014, Pages 5986-5994

  Sullivan, Erin M ^a   Jeha, Sima ^a,b   Kang, Guolian ^a   Cheng, Cheng ^a   Rooney, Barbara ^a   Holladay, Martha ^a   Bari, Rafijul ^a   Schell, Sarah ^a   Tuggle, Macal ^a   Pui, Ching Hon ^a,b   Leung, Wing ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE MACROGOL; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; ENZYME INHIBITOR; FAS LIGAND; GRANZYME B; HLA C ANTIGEN; HYDROCORTISONE; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL5; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL5A; LIGAND; MERCAPTOPURINE; METHOTREXATE; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; PREDNISONE; TIOGUANINE; UNCLASSIFIED DRUG; VINCRISTINE; BIOLOGICAL MARKER; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; MESSENGER RNA; NATURAL KILLER CELL RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; CANCER DIAGNOSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; INDUCTION CHEMOTHERAPY; KIR2DL5A GEME; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; NATURAL KILLER CELL; PHENOTYPE; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TELOMERE; ADOLESCENT; CHILD; GENETICS; IMMUNOLOGY; INFANT; METABOLISM; PATHOLOGY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD; REMISSION; TREATMENT OUTCOME;

ADOLESCENT; BIOMARKERS; CHILD; CHILD, PRESCHOOL; FEMALE; GENOTYPE; HUMANS; IMMUNOPHENOTYPING; INFANT; KILLER CELLS, NATURAL; MALE; NEOPLASM, RESIDUAL; PHENOTYPE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECEPTORS, KIR; RECEPTORS, NATURAL KILLER CELL; REMISSION INDUCTION; RNA, MESSENGER; ROC CURVE; TREATMENT OUTCOME;

EID: 84918771857     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0479     Document Type: Article

References (50)

1. Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 2000;356:1795-9.
2. Caligiuri MA. Human natural killer cells. Blood 2008;112:461-9.
3. Costello RT, Sivori S, Marcenaro E, Lafage-Pochitaloff M, Mozziconacci MJ, Reviron D, et al. Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood 2002;99:3661-7.
4. Fauriat C, Just-Landi S, Mallet F, Arnoulet C, Sainty D, Olive D, et al. Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. Blood 2007;109:323-30.
5. Nasrallah AG, Miale TD. Decreased natural killer cell activity in children with untreated acute leukemia. Cancer Res 1983;43:5580-5.
6. Dickinson AM, Proctor SJ, Jacobs E, Reid MM, Walker W, Craft AW, et al. Natural killer cell activity in childhood acute lymphoblastic leukaemia in remission. Br J Haematol 1985;59:45-53.
7. Leung W. Use of NK cell activity in cure by transplant. Br J Haematol 2011;155:14-29.
8. Velardi A, Ruggeri L, Mancusi A. Killer-cell immunoglobulin-like receptors reactivity and outcome of stem cell transplant. Curr Opin Hematol 2012;19:319-23.
9. Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. Lancet 2013;381:1943-55.
10. Campana D. Minimal residual disease in acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2010;2010: 7-12.
11. Bari R, Rujkijyanont P, Sullivan E, Kang G, Turner V, Gan K, et al. Effect of donor KIR2DL1 allelic polymorphism on the outcome of pediatric allogeneic hematopoietic stem-cell transplantation. J Clin Oncol 2013;31:3782-90.
12. Thompson A, van der Slik AR, Koning F, van Bergen J. An improved RT-PCR method for the detection of killer-cell immunoglobulin-like receptor (KIR) transcripts. Immunogenetics 2006;58:865-72.
13. Youden WJ. Index for rating diagnostic tests. Cancer 1950;3:32-5.
14. + to analyze and compare ROC curves. BMC Bioinformatics 2011;12:77.
15. R Development Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2010.
16. Gonzalez-Galarza FF, Christmas S, Middleton D, Jones AR. Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acids Res 2011;39: D913-9.
17. Screpanti V, Wallin RP, Grandien A, Ljunggren HG. Impact of FASL-induced apoptosis in the elimination of tumor cells by NK cells. Mol Immunol 2005;42:495-9.
18. Bari R, Bell T, Leung WH, Vong QP, Chan WK, Das Gupta N, et al. Significant functional heterogeneity among KIR2DL1 alleles and a pivotal role of arginine 245. Blood 2009;114:5182-90.
19. Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol 2005;5:201-14.
20. Symons HJ, Leffell MS, Rossiter ND, Zahurak M, Jones RJ, Fuchs EJ. Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype Bdonors after nonmyeloablative, HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant 2010;16:533-42.
21. Cooley S, Weisdorf DJ, Guethlein LA, Klein JP, Wang T, Le CT, et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood 2010;116:2411-9.
22. Verheyden S, Bernier M, Demanet C. Identification of natural killer cell receptor phenotypes associated with leukemia. Leukemia 2004;18:2002-7.
23. McQueen KL, Dorighi KM, Guethlein LA, Wong R, Sanjanwala B, Parham P. Donor-recipient combinations of group A and B KIR haplotypes and HLA class I ligand affect the outcome of HLA-matched, sibling donor hematopoietic cell transplantation. Hum Immunol 2007;68:309-23.
24. La Nasa G, Caocci G, Littera R, Atzeni S, Vacca A, Mulas O, et al. Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients. Exp Hematol 2013;41:424-31.
25. Kroger N, Binder T, Zabelina T, Wolschke C, Schieder H, Renges H, et al. Low number of donor activating killer immunoglobulin-like receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukemia patients after in vivo T-cell depleted unrelated stem cell transplantation. Transplantation 2006;82:1024-30.
26. Parham P. Immunogenetics of killer-cell immunoglobulin-like receptors. Tissue Antigens 2003;62:194-200.
27. Goodridge JP, Lathbury LJ, Steiner NK, Shulse CN, Pullikotil P, Seidah NG, et al. Three common alleles of KIR2DL4 (CD158d) encode constitutively expressed, inducible and secreted receptors in NK cells. Eur J Immunol 2007;37:199-211.
28. Middleton D, Gonzalez A, Gilmore PM. Studies on the expression of the deleted KIR2DS4∗003 gene product and distribution of KIR2DS4 deleted and nondeleted versions in different populations. Hum Immunol 2007;68:128-34.
29. Chewning JH, Gudme CN, Hsu KC, Selvakumar A, Dupont B. KIR2DS1-positive NK cells mediate alloresponse against the C2 HLA-KIR ligand group in vitro. J Immunol 2007;179:854-68.
30. Pittari G, Liu XR, Selvakumar A, Zhao Z, Merino E, Huse M, et al.NKcell tolerance of self-specific activating receptor KIR2DS1 in individuals with cognate HLA-C2 ligand. J Immunol 2013;190:4650-60.
31. Leung W, Iyengar R, Triplett B, Turner V, Behm FG, Holladay MS, et al. Comparison of killer Ig-like receptor genotyping and phenotyping for selection of allogeneic blood stem cell donors. J Immunol 2005;174: 6540-5.
32. McErlean C, Gonzalez AA, Cunningham R, Meenagh A, Shovlin T, Middleton D. Differential RNA expression of KIR alleles. Immunogenetics 2010;62:431-40.
33. Fernandez NC, Treiner E, Vance RE, Jamieson AM, Lemieux S, Raulet DH. A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules. Blood 2005;105:4416-23.
34. Anfossi N, Andre P, Guia S, Falk CS, Roetynck S, Stewart CA, et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity 2006;25:331-42.
35. Hasenkamp J, Borgerding A, Uhrberg M, Falk C, Chapuy B, Wulf G, et al. Self-tolerance of human natural killer cells lacking self-HLA-specific inhibitory receptors. Scand J Immunol 2008;67:218-29.
36. Kim S, Poursine-Laurent J, Truscott SM, Lybarger L, Song YJ, Yang L, et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 2005;436:709-13.
37. Yokoyama WM, Kim S. How do natural killer cells find self to achieve tolerance? Immunity 2006;24:249-57.
38. Yokoyama WM, Kim S. Licensing of natural killer cells by self-major histocompatibility complex class I. Immunol Rev 2006;214:143-54.
39. Karre K. NK cells, MHC class I molecules and the missing self. Scand J Immunol 2002;55:221-8.
40. Yu J, Heller G, Chewning J, Kim S, Yokoyama WM, Hsu KC. Hierarchy of the human natural killer cell response is determined by class and quantity of inhibitory receptors for self-HLA-B and HLA-C ligands. J Immunol 2007;179:5977-89.
41. Joncker NT, Fernandez NC, Treiner E, Vivier E, Raulet DH. NK cell responsiveness is tuned commensurate with the number of inhibitory receptors for self-MHC class I: the rheostat model. J Immunol 2009;182:4572-80.
42. Raulet DH, Vance RE. Self-tolerance of natural killer cells. Nat Rev Immunol 2006;6:520-31.
43. Joncker NT, Raulet DH. Regulation of NK cell responsiveness to achieve self-tolerance and maximal responses to diseased target cells. Immunol Rev 2008;224:85-97.
44. Cooley S, Xiao F, Pitt M, Gleason M, McCullar V, Bergemann TL, et al. A subpopulation of human peripheral blood NK cells that lacks inhibitory receptors for self-MHC is developmentally immature. Blood 2007;110:578-86.
45. Montaldo E, Del Zotto G, Della Chiesa M, Mingari MC, Moretta A, De Maria A, et al. Human NK cell receptors/markers: a tool to analyze NK cell development, subsets and function. Cytometry A 2013;83:702-13.
46. Leung W. Infusions of allogeneic natural killer cells as cancer therapy. Clin Cancer Res 2014;20:3390-400.
47. Screpanti V, Wallin RP, Ljunggren HG, Grandien A. A central role for death receptor-mediated apoptosis in the rejection of tumors by NK cells. J Immunol 2001;167:2068-73.
48. Classen CF, Ushmorov A, Bird P, Debatin KM. The granzyme B inhibitor PI-9 is differentially expressed in all main subtypes of pediatric acute lymphoblastic leukemias. Haematologica 2004;89:1314-21.
49. Cunningham TD, Jiang X, Shapiro DJ. Expression of high levels of human proteinase inhibitor 9 blocks both perforin/granzyme and Fas/Fas ligand-mediated cytotoxicity. Cell Immunol 2007;245:32-41.
50. Pui CH, Campana D, Pei D, Bowman WP, Sandlund JT, Kaste SC, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 2009;360:2730-41.